HDV evolution-will viral resistance be an issue in HDV infection?

Curr Opin Virol. 2018 Oct:32:100-107. doi: 10.1016/j.coviro.2018.10.003. Epub 2018 Nov 8.

Abstract

Hepatitis D virus (HDV) is a hepatotropic subviral infectious agent, obligate satellite of the Hepatitis B virus (HBV) and is highly related to viroids. HDV affects around 5% of the 257 million chronic HBV-carriers worldwide, leading to the most severe form of chronic viral hepatitis. Interferon alpha is the only approved treatment for chronic hepatitis D, albeit with low response rates (around 20%-30%). New antiviral strategies are currently under study. Due to the high viral evolution rates (10-3 to 10-4 substitutions/site/year) HDV forms an extremely complex viral population (quasispecies) that can be studied by Next-Generation Sequencing. Therefore, although specific viral resistance in HDV infection has not been reported, it cannot be completely discarded.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Drug Resistance, Viral / genetics*
  • Evolution, Molecular*
  • Genetic Variation*
  • Hepatitis B / virology
  • Hepatitis D / drug therapy*
  • Hepatitis D, Chronic / drug therapy
  • Hepatitis D, Chronic / virology
  • Hepatitis Delta Virus / drug effects
  • Hepatitis Delta Virus / genetics*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Interferon-alpha / therapeutic use
  • Quasispecies / genetics
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Interferon-alpha